Vident Investment Advisory’s Tvardi Therapeutics TVRD Stock Holding History

Vident Investment Advisory’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,396	Closed	-$550K	–	1122
2023 Q2	$550K	Buy	5,396 +968	+22%	+$133K	0.02%	663
2023 Q1	$783K	Buy	4,428 +911	+26%	+$305K	0.03%	605
2022 Q4	$1.36M	Sell	3,517 -71	-2%	-$27K	0.05%	414
2022 Q3	$1.21M	Buy	3,588 +238	+7%	+$86.2K	0.04%	526
2022 Q2	$1.1M	Buy	3,350 +350	+12%	+$123K	0.03%	589
2022 Q1	$1.31M	Buy	3,000 +1,295	+76%	+$532K	0.03%	599
2021 Q4	$748K	Buy	1,705 +67	+4%	+$33.7K	0.02%	814
2021 Q3	$911K	Buy	+1,638	New	+$822K	0.03%	708

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Vident Investment Advisory's TVRD Position: Q3 2023 in Review

Vident Investment Advisory sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 5,396 shares — an estimated $550K sold.

Vident Investment Advisory first reported a position in TVRD in Q3 2021 and held it in 8 quarters. The position peaked at $1.36M in Q4 2022. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Vident Investment Advisory reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 5,396 Tvardi Therapeutics shares in Q3 2023, an estimated $550K.
Vident Investment Advisory first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 8 quarters.
Vident Investment Advisory's Tvardi Therapeutics position peaked at $1.36M in Q4 2022.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.